Brain Insulin Resistance and Its Impact on Whole-Body Metabolism

Exercise produces profound mood benefits through complex neurobiological mechanisms. A 2013 meta-analysis confirmed exercise alleviates depression symptoms across 39 studies. While endorphins increase dramatically during exercise, they cannot cross the blood-brain barrier due to molecular size limitations. Instead, endocannabinoids like anandamide cross into the brain, producing anti-anxiety and euphoric effects. Simultaneously, exercise elevates serotonin and norepinephrine neurotransmitters, which correlate with improved mood. Myokines, compounds secreted by contracting muscles, create additional benefits: PGC-1α improves exercise efficiency while protecting against stress-induced depression through kynurenine pathway modulation.

Exercise improves Parkinson's disease symptoms through multiple neurobiological mechanisms: it increases neurotrophic factors that protect dopaminergic neurons, reduces oxidative stress and neuroinflammation, improves mitochondrial function, enhances neurotransmitter balance (particularly dopamine and acetylcholine), and promotes angiogenesis; these effects collectively support motor function, cognitive performance, and overall quality of life in Parkinson's patients.

Exercise creates new neural connections in the brain, similar to how patterns are formed in obsessive-compulsive behaviors. The brain continues to reconfigure neurons throughout life based on how we live. Exercise stimulates neurobiological changes that can improve creativity, memory, and cognitive function.

Running stimulates neurogenesis (formation of new brain cells), improves concentration, reaction time, and memory. It increases production of endorphins, serotonin, and dopamine, generating emotional well-being while reducing cortisol (stress hormone) levels. During exercise, the brain releases multiple neurotransmitters: Dopamine (motivation, learning, reward), Noradrenaline (attention, focus), Serotonin (mood, emotional balance), and Endocannabinoids (relaxation, pleasure). BDNF (Brain-Derived Neurotrophic Factor) acts like fertilizer for the nervous system, protecting neurons, stimulating new connections, and promoting brain plasticity. For decades, scientists believed the adult brain couldn't change, but research now shows the brain remains highly adaptable throughout life, and exercise is a natural stimulator of BDNF production.

Exercise acts as a systemic intervention that influences nearly all organs through the production of exercise-responsive molecules called 'exercitins,' which travel through the bloodstream to the central nervous system. These molecules trigger a cascade of neurobiological changes across three levels: cellular and molecular alterations, structural and functional changes in the nervous system, and behavioral/socioemotional adaptations. The key mediator of these effects is BDNF (Brain-Derived Neurotrophic Factor), which promotes neurogenesis, synaptogenesis, and synaptic strengthening. Research demonstrates that exercise-induced changes in neural networks and BDNF levels have predictive power for chronic cognitive adaptations, with the effects following a dose-response relationship where greater exercise intensity and duration lead to more pronounced neurobiological responses.

SGLT2 inhibitors cross the blood-brain barrier (ratio 0.3-0.5) and may benefit cognitive function through multiple mechanisms: reducing inflammation, inhibiting NLRP3 inflammasome, increasing anti-inflammatory M2 macrophages, downregulating STAT1, and reducing oxidative stress. They also modulate mTOR signaling by mimicking fasting effects, restoring cyclic patterns that prevent hyperactivation causing endothelial dysfunction and cognitive impairment. Clinical evidence includes reduced dementia risk (OR 0.75), less Alzheimer's/Parkinson's development, and improved MoCA scores and functional mobility after just one month of treatment in frail patients with diabetes and heart failure.

This section explains the pharmacological mechanisms of SGLT2 inhibitors. The drugs work by blocking SGLT2 receptors in the proximal renal tubule, which normally reabsorbs 90% of filtered glucose. This inhibition causes glucose excretion in urine along with sodium and water. Three observations support this mechanism: SGLT2 receptor overexpression in diabetic patients, increased glucose reabsorption with hyperglycemia, and lowered glucose excretion threshold in diabetic patients. The hemodynamic effects include increased urine output reducing plasma volume, decreasing cardiac preload and improving cardiac efficiency. The cellular effects involve reducing intracellular sodium and calcium while increasing mitochondrial calcium, improving cellular energy production. The drugs also shift metabolism toward fatty acid oxidation, which provides higher ATP yield than glucose metabolism.

SGLT2 inhibitors protect the kidneys through indirect and direct mechanisms. Indirect effects include improved glycemic control, enhanced insulin sensitivity, weight loss, blood pressure reduction, and uric acid lowering (~10%). Direct effects involve reducing intra-glomerular pressure (similar to ACE inhibitors), decreasing urea production (30-50%), and reducing glomerular and interstitial injury, inflammation, oxidative stress, and improving kidney oxygenation. The key mechanism involves blocking the SGLT2 transporter in the proximal tubule, which normally reabsorbs sodium and glucose.

SGLT2 inhibitors work through three interconnected mechanisms: (1) Glucose toxicity reduction - high glucose damages heart muscle cells, and promoting glucose excretion reduces this toxicity; (2) Insulin resistance as protection - the body develops insulin resistance to protect organs from overnutrition, and SGLT2 inhibitors help manage this; (3) Glucotoxicity - prolonged high glucose exposure reduces beta cell insulin production, and normalizing glucose levels can restore function. These mechanisms explain why SGLT2 inhibitors benefit both diabetic and non-diabetic patients with metabolic dysfunction.

Henagliflozin works as an SGLT2 inhibitor, blocking kidney glucose reabsorption to lower blood sugar through urinary excretion. However, this triggers broader metabolic and hormonal cascades that induce a fasting-like state. This explains enhanced immune function (activated cytotoxic T cells with improved weaponry) and the metabolic signature of calorie restriction (elevated ketones, thiamine, and reduced stress fats). Other available SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) likely share these anti-aging mechanisms, with empagliflozin and dapagliflozin already proven to reduce cellular senescence and extend mouse lifespan.

Alzheimer's involves insulin gene dysfunction in the hippocampus. Healthy individuals have highly active genes that produce insulin and help it work better, while Alzheimer's patients have weakened insulin-producing genes and activated genes that inhibit insulin function. This prevents neurons from receiving energy, causing cell death. Clinical trials are testing intranasal insulin delivery, where a device delivers insulin through each nostril for 20 seconds. Results show reduced damage in brain regions and smaller cognitive decline in patients receiving the most insulin.

Metabolic dysfunction, particularly insulin resistance and altered energy metabolism, significantly impacts cognitive function in aging populations, including those living with HIV; research demonstrates that subclinical metabolic changes—such as elevated insulin levels, abnormal C-peptide to insulin ratios, and lipid profile alterations—can predict cognitive decline even before reaching clinical thresholds for metabolic syndrome, and promoting anaerobic glycolysis through interventions like intranasal insulin delivery may offer neuroprotective benefits by shifting brain energy metabolism toward more efficient fatty acid beta-oxidation pathways.

Alzheimer's disease is characterized by 'type 3 diabetes of the brain' due to insulin resistance impairing glucose uptake in key brain regions like the hippocampus. PET scans reveal dramatically reduced glucose metabolism in Alzheimer's brains compared to healthy controls. Type 2 diabetes doubles Alzheimer's risk, though peripheral treatments don't address brain-specific insulin resistance. Intranasal insulin administration bypasses systemic barriers to deliver insulin directly to brain regions, enhancing cellular energy production and supporting cognitive function. This approach has shown memory improvement in healthy adults and cognitive benefits in Alzheimer's patients. Beyond Alzheimer's, intranasal insulin shows potential for treating multiple sclerosis by signaling oligodendrocytes to improve remyelination, and for post-traumatic stress disorder by attenuating stress hormone responses. The versatility of intranasal delivery extends to various therapeutic agents including iron-binding drugs, gene therapies, and anti-tumor cells, representing a transformative approach for treating previously untreatable brain diseases.

Nasal insulin administration may enhance cognitive function by bypassing systemic circulation and delivering insulin directly to the hypothalamus. This could open insulin-dependent glucose transporters (GLUT4) in brain cells, allowing increased glucose uptake. The effect is modest and direct, with no systemic insulin elevation. This mechanism may explain why nasal insulin is being researched for Alzheimer's treatment and cognitive enhancement.

The blood-brain barrier limits molecule movement from blood to brain, hindering CNS treatment development. Intranasal delivery provides a non-invasive bypass using olfactory nerve pathways, delivering therapeutics directly to the brain within minutes. This method reduces systemic concentrations and side effects. The olfactory nerve pathway works because olfactory receptor neurons lack tight junctions and regenerate every 30 days, creating open channels connecting nasal passages directly to the brain. Glucose hypometabolism characterizes many CNS disorders including Alzheimer's, Parkinson's, TBI, and SCI. Insulin promotes glucose uptake but faces restricted passage through the blood-brain barrier when administered systemically. Intranasal delivery targets insulin directly to the brain, increasing glucose uptake for cellular energy and demonstrating improved memory and function in clinical trials across multiple neurological conditions with minimal side effects.